Orthocell has announced that the US Food and Drug Administration has granted regulatory clearance under the 510(k) pathway for the Company’s nerve repair product, Remplir™
First Sales of Striate+â„¢ in DACH Region
Orthocell has today announced that our exclusive global distribution partner BioHorizons has officially completed first sales of Orthocell’s dental product, Striate+™, in Germany, Austria and Switzerland.
Orthocell Receives Regulatory Approval for Striate+ in Singapore
Orthocell has received regulatory approval from Singapore’s Health Sciences Authority (HSA) for its market leading dental guided bone regeneration product, Striate+â„¢.
REPLAY | Investor Webinar
Orthocell CEO and MD, Paul Anderson, hosted a webinar this morning to provide an important update on Orthocell’s clinical and commercial plans.
Watch the replay:
Thailand Regulatory Application for Remplirâ„¢
Orthocell has submitted a regulatory application to the FDA of Thailand to commence sales of its groundbreaking nerve repair device Remplirâ„¢, with clearance expected in Q3 CY2025.
Orthocell Submits Canada Regulatory Application to Commence Sales of Remplirâ„¢ into US$75million Canadian market
Orthocell has announced it has submitted an application to Health Canada for a Medical Device Licence (MDL) to sell its leading nerve repair product Remplirâ„¢ into the US$75 million Canadian nerve repair market.
Stockhead | Orthocell soars 14% after crushing early sales growth for Remplir
Orthocell’s plans to broaden its commercial footprint in existing and new markets drove the company’s share price up 13.8% this week, according to a special report in Stockhead.
Orthocell Accelerates Global Expansion: Five New Country Regulatory Submissions Planned in 2025
On the back of outstanding early sales traction for Remplirâ„¢ in Australia, New Zealand and Singapore, Orthocell has announced that it is accelerating its global expansion into multiple key jurisdictions.Â
Orthocell receives $3.18m R&D tax incentive refund
Orthocell has announced that it has received a $3.18 million R&D Tax Incentive Refund for the 2023/2024 financial year.
Stockhead Special Report | Orthocell achieves third consecutive quarter of record revenue
Orthocell has been featured in a special report on Stockhead highlighting Orthocell’s consistent growth in sales of our regenerative medicine products, Striate+ and Remplir.